| Post-COVID-19 global health strategies: the need for an interdisciplinary approach Aging clinical and experimental research 32 (8), 1613-1620, 2020 | 341 | 2020 |
| Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line A Ciccullo, A Borghetti, LZ Dal Verme, A Tosoni, F Lombardi, M Garcovich, ... International journal of antimicrobial agents 56 (2), 106017, 2020 | 169 | 2020 |
| Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial F Perrone, MC Piccirillo, PA Ascierto, C Salvarani, R Parrella, AM Marata, ... Journal of translational medicine 18 (1), 405, 2020 | 153 | 2020 |
| Off‐label use of tocilizumab in patients with SARS‐CoV‐2 infection S Di Giambenedetto, A Ciccullo, A Borghetti, G Gambassi, F Landi, ... Journal of medical virology 92 (10), 1787, 2020 | 140 | 2020 |
| Incidence of deep vein thrombosis among non‐ICU patients hospitalized for COVID‐19 despite pharmacological thromboprophylaxis A Santoliquido, A Porfidia, A Nesci, G De Matteis, G Marrone, E Porceddu, ... Journal of Thrombosis and Haemostasis 18 (9), 2358-2363, 2020 | 121 | 2020 |
| Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study A Di Castelnuovo, S Costanzo, A Antinori, N Berselli, L Blandi, ... Thrombosis and haemostasis 121 (08), 1054-1065, 2021 | 105 | 2021 |
| Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study A Di Castelnuovo, S Costanzo, A Antinori, N Berselli, L Blandi, R Bruno, ... European Journal of Internal Medicine 82, 38-47, 2020 | 96 | 2020 |
| Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with … R Gagliardini, A Ciccullo, A Borghetti, F Maggiolo, D Bartolozzi, V Borghi, ... Open forum infectious diseases 5 (6), ofy113, 2018 | 79 | 2018 |
| Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients G Baldin, A Ciccullo, S Rusconi, A Capetti, G Sterrantino, M Colafigli, ... International journal of antimicrobial agents 54 (6), 728-734, 2019 | 56 | 2019 |
| Assessment of neurological manifestations in hospitalized patients with COVID‐19 M Luigetti, R Iorio, AR Bentivoglio, L Tricoli, V Riso, J Marotta, C Piano, ... European journal of neurology 27 (11), 2322-2328, 2020 | 54 | 2020 |
| COVID-19 and intestinal inflammation: Role of fecal calprotectin V Ojetti, A Saviano, M Covino, N Acampora, E Troiani, F Franceschi, ... Digestive and Liver Disease 52 (11), 1231-1233, 2020 | 52 | 2020 |
| Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV‐1 replication A Borghetti, G Baldin, F Lombardi, A Ciccullo, A Capetti, S Rusconi, ... HIV medicine 19 (7), 452-454, 2018 | 51 | 2018 |
| A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients A Ciccullo, G Baldin, A Capetti, S Rusconi, G Sterrantino, G d'Ettorre, ... Antiviral therapy 24 (1), 63-67, 2019 | 41 | 2019 |
| Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice G Baldin, A Ciccullo, A Borghetti, S Di Giambenedetto Journal of Antimicrobial Chemotherapy 74 (5), 1461-1463, 2019 | 39 | 2019 |
| RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies A Di Castelnuovo, S Costanzo, A Antinori, N Berselli, L Blandi, ... Vascular Pharmacology 135, 106805, 2020 | 37 | 2020 |
| Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study B Rossetti, G Baldin, G Sterrantino, S Rusconi, A De Vito, A Giacometti, ... Antiviral research 169, 104552, 2019 | 33 | 2019 |
| Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective … A Borghetti, F Lombardi, R Gagliardini, G Baldin, A Ciccullo, D Moschese, ... BMC infectious diseases 19, 1-9, 2019 | 31 | 2019 |
| Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding A Ciccullo, V Borghi, A Giacomelli, MV Cossu, G Sterrantino, A Latini, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 88 (3), 234-237, 2021 | 28 | 2021 |
| Efficacy and durability of two‐ vs. three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE … M Fabbiani, B Rossetti, A Ciccullo, L Oreni, F Lagi, L Celani, M Colafigli, ... HIV medicine 22 (9), 843-853, 2021 | 26 | 2021 |
| Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy A Borghetti, G Baldin, A Ciccullo, R Gagliardini, A D'Avino, A Mondi, ... Journal of Antimicrobial Chemotherapy 71 (8), 2359-2361, 2016 | 26 | 2016 |
